Tag: BNO
Bionomics publishes BNC210 anti-anxiety trial data in Biological Psychiatry, prepares for next study
Bionomics (ASX: BIO) has published data regarding its phase 2a trial into using its BNC210 drug to treat generalised anxiety disorder (GAD) patients.
The company’s paper Cholinergic Modulation of D...
Bionomics sells French subsidiaries to focus on PTSD drug development
Clinical stage biopharmaceutical company Bionomics (ASX: BNO) has completed the sale of two wholly-owned subsidiaries to French company Domain Therapeutics for €1.79 million (A$3.04 million).
The s...
Bionomics on fast track to developing a treatment for post-traumatic stress disorder
Clinical stage biopharma company Bionomics (ASX: BNO) is celebrating this morning after being granted “fast track designation” for its BNC210 development program for the treatment of post-traumatic st...
Bionomics’ PTSD drug on track for further clinical studies
Biopharma company Bionomics (ASX: BNO) has updated the market with positive news regarding its leading drug candidate BNC210, a potentially new way of treating patients with post-traumatic stress diso...
Further analysis provides greater insight into phase 2 findings of Bionomics’ PTSD drug
Biopharmaceutical company Bionomics (ASX: BNO) has reported positive results from further data analysis of a phase two trial involving the BNC210 drug to treat post traumatic stress disorder.
The a...
Bionomics and US drugmaker Bristol-Myers Squibb kick off experimental cancer trial
Biopharmaceutical company Bionomics (ASX: BNO) has begun the first experimental trial of its proposed cancer drug, BNC105, which will roll out at 15 sites across Australia.
The trial, which has com...
